IL256912B2 - Methods of treating developmental disorders with gaboxadol - Google Patents

Methods of treating developmental disorders with gaboxadol

Info

Publication number
IL256912B2
IL256912B2 IL256912A IL25691218A IL256912B2 IL 256912 B2 IL256912 B2 IL 256912B2 IL 256912 A IL256912 A IL 256912A IL 25691218 A IL25691218 A IL 25691218A IL 256912 B2 IL256912 B2 IL 256912B2
Authority
IL
Israel
Prior art keywords
gaboxadol
patient
pharmaceutical composition
pharmaceutically acceptable
hours
Prior art date
Application number
IL256912A
Other languages
English (en)
Hebrew (he)
Other versions
IL256912A (en
IL256912B1 (en
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of IL256912A publication Critical patent/IL256912A/en
Publication of IL256912B1 publication Critical patent/IL256912B1/en
Publication of IL256912B2 publication Critical patent/IL256912B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL256912A 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol IL256912B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562193717P 2015-07-17 2015-07-17
US201562207595P 2015-08-20 2015-08-20
US201662332567P 2016-05-06 2016-05-06
US201662346763P 2016-06-07 2016-06-07
PCT/US2016/042238 WO2017015049A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
US15/209,862 US20170014393A1 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol

Publications (3)

Publication Number Publication Date
IL256912A IL256912A (en) 2018-03-29
IL256912B1 IL256912B1 (en) 2023-09-01
IL256912B2 true IL256912B2 (en) 2024-01-01

Family

ID=57774846

Family Applications (2)

Application Number Title Priority Date Filing Date
IL256912A IL256912B2 (en) 2015-07-17 2016-07-14 Methods of treating developmental disorders with gaboxadol
IL305342A IL305342B1 (en) 2015-07-17 2016-07-14 Geboxadol and pharmaceutical preparations containing it for use in the treatment of Engelman syndrome

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL305342A IL305342B1 (en) 2015-07-17 2016-07-14 Geboxadol and pharmaceutical preparations containing it for use in the treatment of Engelman syndrome

Country Status (17)

Country Link
US (8) US20170014393A1 (enExample)
EP (2) EP4541420A3 (enExample)
JP (3) JP2018520189A (enExample)
KR (2) KR20180031721A (enExample)
CN (2) CN116531370A (enExample)
AU (2) AU2016295138B2 (enExample)
BR (1) BR112018000933A2 (enExample)
CA (1) CA2992734A1 (enExample)
CL (1) CL2018000142A1 (enExample)
CO (1) CO2018000375A2 (enExample)
ES (1) ES3021189T3 (enExample)
HK (1) HK1250951A1 (enExample)
IL (2) IL256912B2 (enExample)
MX (2) MX391708B (enExample)
PE (2) PE20230735A1 (enExample)
TW (2) TW202325293A (enExample)
WO (1) WO2017015049A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS62007B1 (sr) 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
EP4541420A3 (en) 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) * 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) * 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus
US20180338959A1 (en) * 2017-05-24 2018-11-29 Ovid Therapeutics Inc. Treatment of depressive disorders
JP2020529440A (ja) 2017-08-04 2020-10-08 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 糖尿病および関連する状態の処置におけるガボキサドールの使用
EP3711761A4 (en) * 2017-11-14 2021-11-24 SK Biopharmaceuticals Co., Ltd. USE OF A CARBAMATE COMPOUND TO REDUCE OR TREAT DEVELOPMENTAL DISORDERS, INCLUDING FRAGILE X SYNDROME, ANGELMAN'S SYNDROME, OR RETT'S SYNDROME
KR20210040358A (ko) * 2018-06-14 2021-04-13 오비드 테라퓨틱스 인크. 안젤만 증후군의 치료에서 mir-92a 또는 mir-145의 사용
CN112888437A (zh) * 2018-08-22 2021-06-01 奥维德医疗公司 加波沙朵在治疗胃肠道紊乱和哮喘中的用途
WO2020061410A1 (en) * 2018-09-20 2020-03-26 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
MX2021005994A (es) * 2018-11-21 2021-09-14 Certego Therapeutics Inc Combinacion de gaboxadol y litio para el tratamiento de trastornos psiquiatricos.
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
WO2020131856A1 (en) 2018-12-17 2020-06-25 Ovid Therapeutics Inc. Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
JP7749169B2 (ja) * 2019-06-07 2025-10-06 クヴァトリス セラピューティクス， インコーポレイテッド 中枢神経系障害を処置するための組成物および方法
AU2020313930A1 (en) * 2019-07-15 2022-02-03 Ovid Therapeutics Inc. Pharmaceutical formulations containing gaboxadol for therapeutic treatment
US11364228B2 (en) 2019-12-18 2022-06-21 Ovid Therapeutics Inc. Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
WO2006013397A1 (en) * 2004-08-06 2006-02-09 Merck Sharp & Dohme Limited Combination of gaboxadol and 5ht2a antagonists
US20080269278A1 (en) * 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830083A (en) 1953-04-29 1958-04-08 Allied Chem & Dye Corp Production of aryloxy aliphatic carboxylic acids
US4084000A (en) 1975-07-16 1978-04-11 Nelson Research And Development Company Method of treating schizophrenia
US4129652A (en) 1976-08-16 1978-12-12 Nelson Research & Development Company Method for potentiating neuroleptic drugs
US4138484A (en) 1976-08-16 1979-02-06 Nelson Research & Development Company Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs
DK270378A (da) 1977-06-20 1978-12-21 Krogsgaard Larsen P Isoxazolderivater
US4362731A (en) 1980-09-01 1982-12-07 Sandoz Ltd. Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof
US4353910A (en) 1981-11-27 1982-10-12 Kefalas A/S Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment
JPS61277618A (ja) 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
DE19525598C2 (de) 1995-07-13 1997-09-25 Max Planck Gesellschaft Schlafmittel
DE19526864A1 (de) 1995-07-22 1997-01-23 Labtec Gmbh Hormonpflaster
US6461644B1 (en) 1996-03-25 2002-10-08 Richard R. Jackson Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
AR031473A1 (es) 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
EP1345602B1 (en) * 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
US20020165217A1 (en) 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
AU2002338855B2 (en) 2001-05-21 2007-08-16 H. Lundbeck A/S Granular preparations of gaboxadol
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US20050234093A1 (en) 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
BRPI0410857A (pt) 2003-06-25 2006-07-04 Lundbeck & Co As H método para o tratamento de depressão, uso de gaboxadol, e, composição farmacêutica
US20070032553A1 (en) 2003-09-10 2007-02-08 Mckernan Ruth Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome
TW200528098A (en) 2003-12-18 2005-09-01 Lundbeck & Co As H Treatment of insomnia in human patients
US20050137222A1 (en) * 2003-12-18 2005-06-23 H. Lundbeck A/S Treatment of insomnia in human patients
US20050215521A1 (en) 2003-12-22 2005-09-29 Karim Lalji Modafinil combination therapy for improving sleep quality
GB0402118D0 (en) * 2004-01-30 2004-03-03 Merck Sharp & Dohme Polymorphic forms of a GABAA agonist
ZA200607427B (en) * 2004-04-02 2009-02-25 Lundbeck & Co As H Treatment of impaired respiratory function with gaboxadol
DE102005020882A1 (de) 2005-05-04 2006-11-09 Dömling, Alexander, Dr. Verwendung von Gaboxadol und Derivaten zur Behandlung von Kinase-induzierten Krankheiten
AU2006308889A1 (en) * 2005-10-31 2007-05-10 Braincells, Inc. GABA receptor mediated modulation of neurogenesis
US20110046090A1 (en) 2005-10-31 2011-02-24 Braincells Inc. Modulation of neurogenesis with gaba agents and gaba analogs
PL2083811T3 (pl) * 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
AU2007346591A1 (en) 2007-02-07 2008-08-14 Gosforth Centre (Holdings) Pty Ltd Treatment of ADHD
US20090269795A1 (en) 2007-03-09 2009-10-29 The Research Foundation Of State University Of New York Mutant alpha4betadelta GABAA receptor and methods of treating anxiety or irritability
TW200920358A (en) 2007-08-13 2009-05-16 Lundbeck & Co As H Method of treating stress-mediated depression
US20090048288A1 (en) 2007-08-13 2009-02-19 H. Lundbeck A/S Method of treating stress-mediated depression
EP2334299A1 (en) * 2008-09-01 2011-06-22 H. Lundbeck A/S Pharmaceutical composition comprising gaboxadol and an inhibitor of patl or oat
US20100286762A1 (en) 2009-03-18 2010-11-11 Musc Foundation For Research Development Compositions and Methods for Ameliorating Clinical Electrical Disturbances
CN102147667A (zh) 2010-02-08 2011-08-10 深圳富泰宏精密工业有限公司 触控笔
DK2621282T3 (da) 2010-09-28 2020-05-04 Univ California Gaba-agonister i behandlingen af forstyrrelser forbundet med metabolisk syndrom og gaba-kombinationer i behandling eller profylakse af type i diabetes
WO2012075286A2 (en) 2010-12-01 2012-06-07 The Regents Of The University Of California Intrapulmonary benzodiazepine for the treatment and prevention of seizures
US9480695B2 (en) 2011-09-29 2016-11-01 The University Of Tokyo Methods for inducing orexin neurons and agent for treating narcolepsy or eating disorder
US20140371210A1 (en) 2011-10-13 2014-12-18 Jaleva Pharmaceuticals, Llc Methods and compositions for rapid transbuccal delivery of active agents
AU2013352141B2 (en) * 2012-11-30 2018-04-05 The Regents Of The University Of California Anticonvulsant activity of steroids
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
RS62007B1 (sr) * 2014-06-06 2021-07-30 Ovid Therapeutics Inc Postupci pojačavanja tonične inhibicije i lečenja angelmanovog sindroma
CA2951497C (en) 2014-06-12 2019-04-09 Pfizer Limited Imidazopyridazine derivatives as modulators of the gabaa receptor activity
US9682069B2 (en) 2015-07-17 2017-06-20 Ovid Therapeutics Inc Methods of treating Dravet syndrome
US20170348232A1 (en) 2016-06-07 2017-12-07 Ovid Therapeutics Inc. Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome
EP4541420A3 (en) * 2015-07-17 2025-06-25 Ovid Therapeutics Inc. Methods of treating developmental disorders with gaboxadol
JP6857647B2 (ja) 2015-08-11 2021-04-14 オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． クリティカル・ケア処置中に用いるための鎮静方法および非経腸製剤
US9399034B1 (en) 2015-08-11 2016-07-26 Ovid Therapeutics Inc Methods of sedation during critical care treatment
US9351968B1 (en) 2015-09-09 2016-05-31 Ovid Therapeutics Inc Methods of treating developmental disorders using pipradrol
DK3364993T3 (da) 2015-10-22 2023-01-09 Cavion Inc Fremgangsmåder til behandling af angelman syndrom
WO2017205606A1 (en) 2016-05-26 2017-11-30 Ovid Therapeutics Inc. Methods of treating behavioral syndromes using pipradrol
EP3481387A4 (en) 2016-08-11 2020-04-08 Ovid Therapeutics Inc METHOD AND COMPOSITIONS FOR TREATING EPILEPTIC DISEASES
CN110225754A (zh) 2016-11-22 2019-09-10 奥维德医疗公司 用氟吡汀治疗发育障碍和/或癫痫发作紊乱的方法
US10071083B2 (en) 2017-02-03 2018-09-11 Ovid Therapeutics Inc Use of gaboxadol in the treatment of tinnitus

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030077297A1 (en) * 1999-02-26 2003-04-24 Feng-Jing Chen Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US20080269278A1 (en) * 2004-04-02 2008-10-30 H. Lundbeck A/S Treatment of Impaired Respiratory Function with Gaboxadol
WO2006013397A1 (en) * 2004-08-06 2006-02-09 Merck Sharp & Dohme Limited Combination of gaboxadol and 5ht2a antagonists
US20090143335A1 (en) * 2007-10-29 2009-06-04 H. Lundbeck A/S Modified absorption formulation of gaboxadol

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EIXOTO M F ET AL,, EFFECTS OF GABAERGIC DRUGS ON RESERPINE-INDUCED ORAL DYSKINESIA, 7 May 2005 (2005-05-07) *
GUNVANT K. THAKER,, BRAIN [GAMMA]-AMINOBUTYRIC ACID ABNORMALITY IN TARDIVE DYSKINESIA : REDUCTION IN CEREBROSPINAL FLUID GABA LEVELS AND THERAPEUTIC RESPONSE TO GABA AGONIST TREATMENT, 1 June 1987 (1987-06-01) *
K. EGAWA ET AL, DECREASED TONIC INHIBITION IN CEREBELLAR GRANULE CELLS CAUSES MOTOR DYSFUNCTION IN A MOUSE MODEL OF ANGELMAN SYNDROME, 5 December 2012 (2012-12-05) *
LOZANO REYMUNDO ET AL,, MODULATION OF THE GABAERGIC PATHWAY FOR THE TREATMENT OF FRAGILE X SYNDROME, 1 January 2014 (2014-01-01) *
OLMOS-SERRANO J. L. ET AL.,, THE GABA(A) RECEPTOR AGONIST THIP AMELIORATES SPECIFIC BEHAVIORAL DEFICITS IN THE MOUSE MODEL OF FRAGILE X SYNDROME, 31 December 2011 (2011-12-31) *

Also Published As

Publication number Publication date
TW201707700A (zh) 2017-03-01
EP3324961B1 (en) 2025-03-19
IL305342A (en) 2023-10-01
CN108024997A (zh) 2018-05-11
CN116531370A (zh) 2023-08-04
MX2018000745A (es) 2018-08-15
MX391708B (es) 2025-03-21
BR112018000933A2 (en) 2018-09-04
EP3324961C0 (en) 2025-03-19
CA2992734A1 (en) 2017-01-26
EP3324961A4 (en) 2019-03-13
JP2021130687A (ja) 2021-09-09
PE20230735A1 (es) 2023-05-03
JP2018520189A (ja) 2018-07-26
US20190321342A1 (en) 2019-10-24
HK1250951A1 (zh) 2019-01-18
TWI819995B (zh) 2023-11-01
TW202325293A (zh) 2023-07-01
KR20180031721A (ko) 2018-03-28
US20230071127A1 (en) 2023-03-09
AU2021250862A1 (en) 2021-11-04
MX2022004734A (es) 2022-05-13
ES3021189T3 (en) 2025-05-26
EP3324961A1 (en) 2018-05-30
AU2016295138A1 (en) 2018-02-08
IL305342B1 (en) 2026-02-01
AU2016295138B2 (en) 2021-11-04
US20190255027A1 (en) 2019-08-22
IL256912A (en) 2018-03-29
US20180338960A1 (en) 2018-11-29
US20170014393A1 (en) 2017-01-19
US20190117632A1 (en) 2019-04-25
IL256912B1 (en) 2023-09-01
CL2018000142A1 (es) 2018-07-13
US20180098974A1 (en) 2018-04-12
EP4541420A2 (en) 2025-04-23
US11096929B2 (en) 2021-08-24
AU2021250862B2 (en) 2023-11-09
JP2023103375A (ja) 2023-07-26
CO2018000375A2 (es) 2018-04-19
WO2017015049A1 (en) 2017-01-26
PE20190338A1 (es) 2019-03-07
EP4541420A3 (en) 2025-06-25
KR20240160666A (ko) 2024-11-11
US12465597B2 (en) 2025-11-11
US20210030727A1 (en) 2021-02-04

Similar Documents

Publication Publication Date Title
IL256912B2 (en) Methods of treating developmental disorders with gaboxadol
US10188635B2 (en) Use of gaboxadol in the treatment of tinnitus
AU2021257943A1 (en) Methods of treating developmental disorders and/or seizure disorders with flupirtine and/or gaboxadol
US10123979B2 (en) Methods of treating developmental disorders with biguanides
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
EP3833351A1 (en) Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering
HK40097170A (zh) 用加波沙朵治疗发育障碍的方法